Adaptimmune
VerifiedDevelops therapies to treat cancer.
Launch date
Employees
Market cap
-
Net debt
-
Enterprise valuation
$207m (Public information from Jul 2024)
Share price
$1.39 ADAP
Company register number 06456741
Milton England (HQ)
Deals in current and previous year:
| USD | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 | 2026 |
|---|---|---|---|---|---|---|---|
| Revenues | 0000 | 0000 | 0000 | 0000 | 0000 | 0000 | 0000 |
| % growth | 253 % | 55 % | 342 % | 122 % | 41 % | (29 %) | 1 % |
| EBITDA | 0000 | 0000 | 0000 | 0000 | 0000 | 0000 | 0000 |
| % EBITDA margin | (3179 %) | (2532 %) | (582 %) | (246 %) | (74 %) | (164 %) | - |
| Profit | 0000 | 0000 | 0000 | 0000 | 0000 | 0000 | 0000 |
| % profit margin | (3287 %) | (2571 %) | (609 %) | (189 %) | (107 %) | (218 %) | (230 %) |
| EV / revenue | 00.0x | 00.0x | 00.0x | 00.0x | 00.0x | 00.0x | 00.0x |
| EV / EBITDA | 00.0x | 00.0x | 00.0x | 00.0x | 00.0x | 00.0x | 00.0x |
| R&D budget | 0000 | 0000 | 0000 | 0000 | 0000 | 0000 | 0000 |
| R&D % of revenue | 2313 % | 1807 % | 470 % | 210 % | - | - | - |
Source: Dealroom estimates
Get premium to view all results
| Date | Investors | Amount | Round |
|---|---|---|---|
| - | investor investor investor investor investor investor investor investor investor investor investor investor investor investor investor investor | $0.0 | round |
| N/A | $0.0 Valuation: $0.0 -109.7x EV/LTM EBITDA | round | |
| N/A | $0.0 | round | |
| N/A | $0.0 | round | |
| N/A | $0.0 | round | |
| investor | $0.0 | round | |
* | $125m | Post IPO Debt | |
| Total Funding | 000k | ||
Related Content
Recent News about Adaptimmune
EditTech stack
Tech stackLearn more about the technologies and tools that this company uses.
Investments by Adaptimmune
Edit
ACQUISITION by Adaptimmune Mar 2023